Supernus and Indivior agreed to an all-stock $1.8 billion merger that will combine their CNS and addiction portfolios. The deal, expected to close in the second half of 2026 subject to approvals, would create a combined company named Supernus, Inc., with Jack Khattar serving as president and CEO. The companies said the transaction targets meaningful R&D and commercial synergies, including planned cost reductions projected at about $125 million in annual savings by end-2027. The structure signals continued consolidation as CNS portfolios mature and investors seek scaled platforms across neurology and psychiatry.